Controlled expression of sa-mRNA

The patented enhanced self-amplifying RNA (saRNA) technology developed at Ghent University represents a major advancement in RNA therapeutics and vaccine development. The platform achieves a more controlled amplification profile, resulting in prolonged protein expression while reducing cellular stress and innate immune activation.

This innovation addresses key limitations of conventional saRNA systems, including excessive reactogenicity and rapid expression kinetics. The enhanced constructs demonstrate sustained and efficient in vivo protein production with improved tolerability, creating opportunities for next-generation vaccines, protein replacement therapies, immunotherapies, gene modulation approaches, and in vivo diagnostics.

The technology is compatible with multiple delivery systems and can be adapted to a broad range of therapeutic payloads and indications. Supported by the translational expertise of PROVAXS and the Faculty of Veterinary Medicine, Ghent University, the platform benefits from advanced preclinical validation capabilities in relevant non-rodent animal models and veterinary patients, accelerating the path toward clinical development in humans.